[HTML][HTML] Turning cold tumors into hot tumors by improving T-cell infiltration
YT Liu, ZJ Sun - Theranostics, 2021 - ncbi.nlm.nih.gov
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …
Bioengineered nanogels for cancer immunotherapy
Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …
Rapid surface display of mRNA antigens by bacteria‐derived outer membrane vesicles for a personalized tumor vaccine
Y Li, X Ma, Y Yue, K Zhang, K Cheng… - Advanced …, 2022 - Wiley Online Library
Therapeutic mRNA vaccination is an attractive approach to trigger antitumor immunity.
However, the mRNA delivery technology for customized tumor vaccine is still limited. In this …
However, the mRNA delivery technology for customized tumor vaccine is still limited. In this …
Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
Current cancer immunotherapy [eg, immune checkpoint blockade (ICB)] only benefits small
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …
A “closed‐loop” therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy
Y Du, R Zhang, J Yang, S Liu, J Zhou… - Advanced Functional …, 2022 - Wiley Online Library
The immunosuppression and immune escape of current immunotherapy result in low
efficacy, and ferroptosis is greatly restricted by the low reactive oxygen species (ROS) …
efficacy, and ferroptosis is greatly restricted by the low reactive oxygen species (ROS) …
Materials engineering strategies for cancer vaccine adjuvant development
Cancer vaccines have emerged as a powerful new tool for cancer immunotherapy.
Adjuvants are vaccine ingredients that enhance the strength, velocity, and duration of the …
Adjuvants are vaccine ingredients that enhance the strength, velocity, and duration of the …
Boosting checkpoint immunotherapy with biomaterials
The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer
treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the …
treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the …
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 …
X Zhang, Z Wei, T Yong, S Li, N Bie, J Li, X Li… - Nature …, 2023 - nature.com
The durable response rate to immune checkpoint blockade such as anti-programmed cell
death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly …
death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Vaccines comprising innovative adjuvants are rapidly reaching advanced translational
stages, such as the authorized nanotechnology adjuvants in mRNA vaccines against COVID …
stages, such as the authorized nanotechnology adjuvants in mRNA vaccines against COVID …